Pfizer Stock: Headed to $42?
Pfizer (NYSE: PFE) has had its ups and downs as a company, but one prognosticator thinks it's got more of the former than the latter coming up. Truist Securities managing director and analyst Gregg Gilbert initiated coverage on the stock Friday with an unhesitant buy recommendation at a price target of $42 per share.
Pfizer is a major pharmaceutical company of long standing, but it has attracted more than its usual interest lately because of what many experts consider to be its leading position in the SARS-CoV-2 coronavirus vaccine "race." Its BNT162b2, being developed with Germany's BioNTech, has shown significant promise in early stage testing, and is now in the thick of a crucial phase 2/3 trial.
Image source: Getty Images.
Source Fool.com
